Anti-IgE monoclonal antibody E26

Drug Profile

Anti-IgE monoclonal antibody E26

Alternative Names: E26; IGE 026

Latest Information Update: 14 Mar 2008

Price : $50

At a glance

  • Originator Genentech; Novartis; Tanox
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic asthma; Allergic rhinitis

Most Recent Events

  • 19 Nov 2003 Suspended - Phase-I for Allergic rhinitis in USA (unspecified route)
  • 19 Nov 2003 Suspended - Phase-I for Allergic asthma in USA (unspecified route)
  • 30 Nov 2000 Phase-I clinical trials for Allergic rhinitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top